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The caspase family of cysteine proteases plays impor-
tant roles in bringing about apoptotic cell death. All
caspases studied to date cleave substrates COOH-termi-
nal to an aspartate. Here we show that the Drosophila
caspase DRONC cleaves COOH-terminal to glutamate as
well as aspartate. DRONC autoprocesses itself following
a glutamate residue, but processes a second caspase,
drICE, following an aspartate. DRONC prefers tetrapep-
tide substrates in which aliphatic amino acids are pres-
ent at the P2 position, and the P1 residue can be either
aspartate or glutamate. Expression of a dominant nega-
tive form of DRONC blocks cell death induced by the
Drosophila cell death activators reaper, hid, and grim,
and DRONC overexpression in flies promotes cell death.
Furthermore, the Drosophila cell death inhibitor DIAP1
inhibits DRONC activity in yeast, and DIAP1’s ability to
inhibit DRONC-dependent yeast cell death is sup-
pressed by HID and GRIM. These observations suggest
that DRONC acts to promote cell death. However,
DRONC activity is not suppressed by the caspase inhib-
itor and cell death suppressor baculovirus p35. We dis-
cuss possible models for DRONC function as a cell death
inhibitor.
Programmed cell death, or apoptosis, is a process by which
organisms remove unwanted or damaged cells during develop-
ment and in the adult (reviewed in Ref. 1). Central components
of this process are a family of cysteine proteases known as
caspases (2). Caspases are translated as inactive precursors
that are cleaved to generate proteolytically active enzymes.
Caspase processing involves one or more cleavages COOH-
terminal to the active site cysteine to produce large and small
subunits. An NH2-terminal prodomain is also often removed.
Studies of the crystal structures of caspases show that large
and small subunits from two precursor molecules assemble to
form an active heterotetramer (3–6). Caspases described to
date all cleave their substrates following aspartate residues
(7–11). Importantly, the sites at which caspase zymogens are
cleaved to generate active tetramers often correspond to con-
sensus caspase target sites. This has suggested that caspases
can function in a cascade in which initiator caspases, activated
by upstream death signals, cleave and activate a set of execu-
tioner caspases that carry out proteolytic cleavages of cellular
proteins (12, 13).
Seven caspases, DCP-1 (14), drICE (15), DCP-2/DREDD (16,
17), DRONC (18), DECAY (19), and two caspases predicted on
the basis of genomic sequence (20) have been identified in
Drosophila. Evidence that caspases are important for cell death
in Drosophila comes from several sets of observations. Expres-
sion of the baculovirus caspase inhibitor p35 or the Drosophila
caspase inhibitor DIAP1 blocks cell death in the fly in a number
of different contexts (reviewed in Ref. 21), including normally
occurring cell death and death induced by overexpression of the
cell death activators reaper (rpr), head involution defective
(hid), and grim (22–26). Dominant negative forms of DCP-2/
DREDD (27) and DRONC (28) (this work) inhibit rpr-, hid-, and
grim-dependent cell death. Mutations in dcp-1 (29), the Dro-
sophila homolog of the caspase-activating adaptor Apaf-1 (27,
30, 31), or heterozygosity for deficiencies that remove the dcp-
2/dredd (17) or dronc loci (28), suppress apoptosis in specific
contexts. Also, immunodepletion of drICE prevents apoptotic
events in cell extracts (32). Finally, mutants that eliminate the
function of a Drosophila caspase inhibitor, DIAP1, result in
massive cell death (33–35), which is associated with an in-
crease in caspase activity (33).
How do the Drosophila caspases function to bring about cell
death in the fly? DCP-1, drICE, DECAY, and one caspase
predicted by genomic sequence (daydream; GenBank™ acces-
sion number AF281077) have short prodomains characteristic
of executioner caspases. In contrast, DCP-2/DREDD and
DRONC have large NH2-terminal prodomains with homology
to mammalian death effector and caspase recruitment do-
mains, respectively. A second caspase predicted by genomic
sequence (dream; GenBank™ accession number AF275814)
has a long prodomain that lacks homology with any known
death regulators. Death effector and caspase recruitment do-
mains in caspases are thought to mediate their recruitment to
death signal-dependent complexes in which activation occurs
in response to oligomerization (reviewed in Ref. 36). Thus DCP-
2/DREDD and DRONC may act as initiator caspases in apo-
ptotic signaling.
In most caspases the catalytic site cysteine (C) is present in
the pentapeptide sequence QAC(R/Q/G)(G/E), in which the
QAC motif is invariant. DRONC is unique among caspases in
that the sequence surrounding the active site is PFCRG (Fig.
1A) (18). Caspase crystal structures indicate that the gluta-
mine at the first position of the canonical caspase pentapeptide
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QACRG is part of the substrate binding pocket. The fact that
DRONC has a proline at this position suggests that it has a
novel substrate specificity. Several Caenorhabditis elegans
caspases, CSP-1a and CSP-2a, with pentapeptide sequences
that differ in the first two pentapeptide positions, SACRG and
VCCRG, respectively, have also been described (37).
Here we show that, unique among caspases characterized to
date, DRONC cleaves tetrapeptide and protein substrates
COOH-terminal to glutamate as well as aspartate residues. A
role for DRONC as a cell death caspase is suggested by the
observations that expression of a dominant negative form of
DRONC blocks cell death, that DRONC expression induces cell
death, and that DRONC interacts with other Drosophila cell
death regulators, including DIAP1, drICE, hid, and grim. In-
terestingly, however, DRONC is not inhibited by baculovirus
p35, which inhibits cell death in flies.
EXPERIMENTAL PROCEDURES
PS-SCL Library Analysis—The substrate specificity of recombinant
DRONC was tested using positional scanning synthetic combinatorial
libraries, as described previously (10, 38).
Recombinant Protein Production, DRONC Microsequencing, and
Caspase Activity Assays—The DRONC coding region was amplified by
polymerase chain reaction and introduced into pET23(a) (Novagen) to
produce pDRONC-His6. This plasmid was used to prepare active
DRONC from Escherichia coli as described for DCP-131-His6 (39). The
subunits were resolved on a 15% SDS-PAGE1 gel and transferred to
polyvinylidene difluoride (Millipore). The membrane was stained with
Coomassie and the smaller band excised. Microsequencing was carried
out at the Caltech Protein Microanalytical Laboratory under the direc-
tion of Gary M. Hathaway. Fluorogenic peptide cleavage assays were
carried out as described (39), using DRONC or DCP-1 at 0.2 mM or 0.2
nM final concentration as specified in the text. AFC-tetrapeptide sub-
strates were purchased from Enzyme Systems (Livermore, CA), includ-
ing the custom made Ac-TQTE-AFC and AC-TQTD-AFC. Bacterially
produced DCP-1-His6 and drICE-His6 have been described (39).
35S-Protein Cleavage Assays—The coding regions for DRONC,
drICE, and DCP-1 were cloned from the yeast expression constructs
into Bluescript KS1 (Stratagene). The coding regions of mutant ver-
sions of these proteins were generated using polymerase chain reaction
and the QuickChange site-directed mutagenesis kit (Stratagene). Se-
quencing verified the existence of the desired mutation and the absence
of other polymerase chain reaction-generated mutations. A transcrip-
tion-coupled rabbit reticulocyte translation system (TNT, Promega)
with Redivue [35S]methionine (Amersham Pharmacia Biotech) was
used to generate 35S-labeled proteins. 2 ml of each 35S-labeled product
was incubated with 2 mM of active caspase or buffer alone in caspase
activity buffer (39) in a total 10-ml volume. The products were resolved
by 15% SDS-PAGE, the proteins transferred to Hybond ECL membrane
(Amersham Pharmacia Biotech). Bio-Max MR-1 film (KODAK) was
used to visualize the labeled fragments.
Characterization of DRONC Activity—The concentration of active
DRONC was determined by active site titration using the active site
inhibitor carbobenzoxy-VAD-fluoromethyl ketone (z-VAD-fmk), as de-
scribed in Ref. 40. The activity of DRONC was measured in triplicate for
each substrate using continuous fluorometric assays as described in
Ref. 33. Appropriate dilutions of enzyme were added to reaction mix-
tures containing substrate and caspase activity buffer (33) in a total
volume of 100 ml. kcat/Km values were calculated as described in Ref. 41.
Yeast Constructs and Assays—Yeast expression plasmids for galac-
tose inducible expression of DCP-1, DIAP1, DIAP2, and P35 have been
previously described (39). pCUP-DIAP1, for copper inducible expression
of DIAP1, pGALL-RPR, pGALL-GRIM, and pGALL-HID have been
previously described (33). The coding region of DRONC was amplified
from a clone (LD12627) obtained from the Berkley Drosophila Genome
project, and cloned into pGALL-(LEU2) (39) to produce pGALL-
DRONC. A DRONC active site mutant, DRONCC318S, was generated by
polymerase chain reaction using a mutagenic oligonucleotide encom-
passing the internal SacII site of DRONC, and cloned to replace the
corresponding section of wild-type DRONC in pGALL-(LEU2), gener-
ating pGALL-DRONCC318S. A section of human PARP encoding amino
acids 1–337, spanning the caspase cleavage site, was amplified from a
HeLa cell Matchmaker library (CLONTECH) and cloned into pADH-
(TRP1) (33) in front of a Myc epitope tag (encoding MEQKLISEED-
LAS), to generate pADH-mycPARP337. A fragment encoding p35 was
excised from pEF-p35 (42) and cloned into pADH-(TRP1) (33) to give
pADH-p35.
W303a yeast were transformed as described previously (39). For
survival assays, transformants were grown in selective liquid medium
to saturation, then pelleted, and resuspended in TE to A600 5 0.02.
Five-fold dilutions were prepared, and 2-ml drops of each solution were
spotted onto selective plates with galactose and 0, 10, or 100 mM CuSO4
as specified. For Western blotting to analyze p35 and PARP cleavage,
transformants were grown in glucose-containing selective medium to
stationary phase, washed in TE and grown in YP medium with galac-
tose for 8 h. Yeast were pelleted, lysed by 2 cycles of boiling, and
vortexing with glass beads in cracking buffer (8 M urea, 5% SDS, 40 mM
Tris, pH 6.8, 0.1 mM EDTA, 1% b-mercaptoethanol, 0.4 mg/ml brom-
phenol blue). Samples were subjected to 12% SDS-PAGE, transferred to
Hybond ECL membrane (Amersham Pharmacia Biotech), and probed
with antibodies recognizing the Myc epitope or p35. Washes were fol-
lowed by incubation with a goat anti-mouse horseradish peroxidase-
conjugated secondary antibody (1:2000), followed by detection with ECL
(Pierce).
Transgenic Drosophila Genetics and Histology—The coding regions
for full-length wild type DRONC, DRONCC318S, GRIM, and HID were
cloned into pGMR (22), and introduced into the Drosophila germline
using standard techniques (43), generating GMR-DRONC GMR-
DRONCC318S, GMR-grim, and GMR-hid flies, respectively. GMR-rpr
(24) and GMR-p35 (22) flies have been described previously. Fixation,
embedding and sectioning of adult fly heads, and acridine orange stain-
ing were carried out as described in Ref. 44.
RESULTS AND DISCUSSION
DRONC Cleaves Itself COOH-terminal to a Glutamate—
Some caspases autocatalytically cleave and activate them-
selves. To determine if and where DRONC cleaves itself we
expressed and purified from E. coli a COOH-terminal His6-
tagged version of DRONC. The purified protein consisted of two
major bands, presumably consisting of the processed large and
small subunits (data not shown). As discussed below, this pro-
tein is active as a caspase. To determine the site of cleavage
between the large and small subunits, Edman degradation
amino-terminal sequencing was performed on the smaller
band. The NH2-terminal sequence determined (Fig. 1A) occurs
COOH-terminal to the sequence TQTE352, suggesting that
DRONC cleaves itself following a glutamate rather than an
aspartate. To test this hypothesis directly we mutated DRONC
TQTE352 to TQTA352. 35S-Labeled wild type DRONC and
DRONC TQTAE352A were generated by in vitro translation and
incubated with bacterially produced DRONC or DCP-1. As
shown in Fig. 1B, DRONC cleaved itself to generate a product
corresponding in size to the prodomain and large subunit. This
band was not seen when DRONC TQTAE352A was the sub-
strate, consistent with the hypothesis that DRONC processes
itself following TQTE352. DCP-1 (Fig. 1B) and drICE (data not
shown) cleaved DRONC at several sites. This cleavage was
unaffected by the presence of the TQTA352 mutation, suggest-
ing that these caspases cleaved elsewhere in DRONC, perhaps
in the DRONC prodomain. To explore the possibility of cleav-
age within the DRONC prodomain we generated a form of
DRONC, DRONCpD4A, in which the P1 aspartates of four po-
tential caspase target sites within the prodomain, DEKD66,
ESVD110, DESD113, and DIVD135, were changed to alanine. As
shown in Fig. 1B, 35S-labeled in vitro translated DRONCpD4A
was still processed by wild type DRONC, but not by DCP-1.
Similar results were obtained with cleavage by drICE (data not
shown). Thus DCP-1 and drICE can process DRONC within the
prodomain, but not at the large-small subunit boundary. If this
processing occurs in vivo it may serve as a point of regulation of
DRONC function.
DRONC Cleaves Peptide Substrates Containing a P1 Gluta-
1 The abbreviations used are: PAGE, polyacrylamide gel electro-
phoresis; PARP, poly(ADP-ribosyl)transferase.
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mate or Aspartate—Positional scanning synthetic combinato-
rial libraries (PS-SCL) have been a useful tool to determine
cleavage site specificities of other caspases (10). The PS-SCL is
composed of three separate sublibraries of 8,000 compounds
each. In each sublibrary, one position is defined with one of 20
amino acids (excluding cysteine), while the remaining two po-
sitions contain a mixture of amino acids present in approxi-
mately equimolar concentrations. Analysis of the three subli-
braries (20 samples each) affords a complete understanding of
the amino acid preferences in the P2, P3, and P4 positions. We
used this approach to characterize DRONC’s preferences for
given amino acids at each of these positions. The positional
scanning synthetic combinatorial libraries available all contain
aspartate at the P1 position. While DRONC cleaves itself after
glutamate, it is also able to cleave protein substrates after
aspartate (below). Thus we reasoned that the existing aspar-
tate-based libraries would yield useful information about
DRONCs cleavage specificity. As shown in Fig. 2A, DRONC
shows a strong preference for Thr, Ile, or Val at the P2 position.
A wider spectrum of amino acids was tolerated at the P3 and P4
positions. This analysis suggests that TATD constitutes an
optimal DRONC P1 aspartate tetrapeptide cleavage site.
The results of the PS-SCL analysis were supported by exper-
iments in which DRONC activity was tested directly with a
number of commonly used tetrapeptide activity substrates.
DRONC showed highest levels of activity with the tetrapep-
tides VEID-AMC and IETD-AMC, and somewhat lower levels
of activity with DEVD-AMC (Fig. 2B). However, little if any
activity was seen with WEHD-AMC or YVAD-AMC, which are
predicted to be poor substrates. Fig. 2B also showed that
DRONC had higher levels of activity with the pentapeptide
GIETD-AMC than with the tetrapeptide IETD-AMC. This, as
well as other observations below, suggests that a P5 residue is
important for optimal DRONC activity.
To further characterize DRONCs cleavage preferences we
carried out assays in which the cleavage activities of DRONC
and DCP-1 were measured for two different peptide substrates:
Ac-TQTE-AFC and Ac-DEVD-AFC (Fig. 2C). Ac-TQTE-AFC is
derived from the known DRONC autoprocessing site and is also
predicted to correspond to a good DRONC cleavage site based
on the results obtained from PS-SCL analysis. Ac-DEVD-AFC
is a tetrapeptide substrate for caspases generally grouped to-
gether as effectors of apoptosis (group II caspases (10)).
DRONCs activity is low in absolute terms compared with
DCP-1. However, DRONC shows a clear cleavage preference
for the Ac-TQTE-AFC substrate over Ac-DEVD-AFC (Fig. 2C).
As expected, DCP-1, which has a common variant of the stand-
ard caspase active site pentapeptide (QACQG), has a strong
preference for the tetrapeptide substrate with a P1 aspartate,
Ac-DEVD-AFC (Fig. 2C) (45). Despite the fact that DRONC
shows relatively low levels of activity with tetrapeptide sub-
strates containing a P1 aspartate, DRONC is efficiently inhib-
ited by the broad range tripeptide caspase inhibitor carboben-
zoxy-VAD-fluoromethyl ketone (z-VAD-fmk) (data not shown).
We wanted to determine DRONC’s P1 specificity with re-
spect to aspartate and glutamate. To do this we synthesized a
second tetrapeptide substrate, Ac-TQTD-AFC, that differs from
Ac-TQTE-AFC only by the P1 residue. We used these sub-
strates to measure DRONCs activity (kcat/Km), as described
under “Experimental Procedures.” We calculated a (kcat/Km) of
2.73 for TQTE-AFC and a (kcat/Km) of 3.36 for TQTD-AFC.
Thus DRONC shows only a slight preference for cleavage of
FIG. 1. Cleavage of DRONC by itself and other caspases. Sequence alignments for the five published Drosophila caspases. Residues shared
by three proteins are lightly shaded, those shared by four proteins more darkly shaded, and those shared by all caspases outlined in black. The
pentapeptide sequence surrounding the caspase active site cysteine and the predicted or demonstrated tetrapeptide cleavage sites in the linker that
separates the large and small subunits of the proteins are boxed. The NH2-terminal sequence determined for the DRONC small subunit from
protein sequencing is underlined (A). Three 35S-labeled in vitro translated versions of DRONC were generated: wild type DRONC (WT), DRONC
in which glutamate 352 in the large-small subunit linker was mutated to alanine (E352A), and a version of DRONC in which the P1 aspartates
of four potential caspase cleavage sites in the prodomain were mutated to alanine (pD4A). These were incubated alone or with bacterially produced
wild type DRONC or DCP-1 as described (“Experimental Procedures”) and processed for SDS-PAGE. DRONC processed wild type DRONC to
generate a product of the size expected for the prodomain and large subunit (arrow). DRONC TETA352 was not processed by DRONC. DCP-1
processing of DRONC gave rise to two bands (A and B) that were unaffected by the presence of the DRONC TETA352 mutation. DCP-1 processing
of DRONC was eliminated when four aspartates in the DRONC prodomain were mutated to alanine (B).
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tetrapeptide substrates with a P1 aspartate over those with a
P1 glutamate. DRONC is, however, a particularly poor catalyst
of tetrapeptide hydrolysis. The calculated (kcat/Km) values for
DRONC are roughly 40–180-fold lower than those described
for caspase-9, which itself is a very inefficient enzyme in isola-
tion as compared with most other caspases (40). This may
reflect the fact that DRONC has an intrinsically low turnover
rate or that we have not identified optimal in vitro assay
conditions. However, DRONC activity may also be regulated
allosterically through interactions with the Drosophila homo-
log of Apaf-1 (variously known as Dapaf-1 (30), HAC-1 (31), and
DARK (27)) in a manner similar to that of mammalian
caspase-9 by Apaf-1 (46). Alternatively, since DRONC shows
similar levels of activity to DCP-1 on the protein substrate
drICE (below), optimal DRONC cleavage may require addi-
tional sequences surrounding the target site.
DRONC and DCP-1 Process drICE COOH-terminal to Aspar-
tate Residues—If DRONC is an apical cell death caspase, likely
substrates include other Drosophila caspases. drICE is a good
candidate to be such a target since immunodepletion experi-
ments show that drICE is required for rpr-dependent apoptotic
events in cell extracts (32), and genetic interactions suggest
that DRONC contributes to rpr-, hid-, and grim-dependent cell
death (see Ref. 28 and below). We generated 35S-labeled in vitro
translated drICE and incubated it with bacterially produced
DRONC or DCP-1. We found, consistent with the observations
of others (28, 45), that drICE was efficiently cleaved by DRONC
and DCP-1. We observed the generation of a band correspond-
ing in size to that of the mature large subunit, Ala29-Asp230
(Fig. 3A, band 3). Several other cleavage products were also
generated. These correspond to full-length drICE lacking the
prodomain, Ala29-Val339 (band 1), and a fragment comprising
the prodomain and large subunit processed at the COOH ter-
minus of the large-small subunit linker region, 1-Asp230 (band
FIG. 2. DRONC cleavage of peptide substrates. Three positional scanning synthetic substrate combinatorial libraries were used to assess the
specificity of DRONC for fluorogenic tetrapeptide substrates. In these libraries the P1 amino acid was aspartate, and the P2, P3, or P4 amino acid
was varied while pools of all amino acids occupied the other positions. The y axis represents rate of AMC production expressed as micromolar/min.
DRONC exhibited marked preference for the aliphatic residues threonine, isoleucine, or valine at the P2 position, but tolerated a wider spectrum
of P3 and P4 amino acids (A). DRONC (0.2 mM) cleaved the fluorogenic substrates GIETD-AMC, VEID-AMC, IETD-AMC, DEVD-AMC, WEHD-
AMC, and YVAD-AMC with varying degrees of efficiency. The asterisk (*) present in the GIETD data points indicates the time at which detection
saturation occurred (B). DRONC (0.2 mM) cleaved Ac-TQTE-AFC (100 mM) and Ac-DEVD-AFC (100 mM). DCP1 (0.2 nM) cleaved Ac-DEVD-AFC (100
mM), but not Ac-TQTE-AFC (100 mM). Note the difference in scales for DRONC and DCP-1 cleavage activities (C).
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2). To show that DRONC and DCP-1 processed drICE at the
proposed natural drICE cleavage site between large and small
subunits, TETD230, we changed this site to TETA230. As shown
in Fig. 3A, DRONC and DCP-1 did not cleave 35S-labeled in
vitro translated drICE TETA230 between the large and small
subunit, implying that they both cleave drICE at TETD230.
These results, taken together with the observed site of DRONC
autoprocessing in bacteria and in vitro, and the results of
tetrapeptide cleavage experiments, argue that DRONC cleaves
following glutamate as well as aspartate. DRONC efficiently
processed drICE at QTETD230. However, it processed DCP-1 at
the equivalent site in the large-small subunit linker, VTETD215
(Fig. 1A), very poorly (data not shown). These results are con-
sistent with the possibility, discussed above in the context of
DRONCs cleavage of tetrapeptide substrates, that the optimal
DRONC peptide substrate is a pentapeptide.
The drICE TETA230 mutant was still cleaved by DCP-1 at
one position, perhaps at the prodomain-large subunit boundary
(Fig. 3). To explore this possibility we altered the P1 aspartate
of the proposed prodomain-large subunit boundary caspase
target site, DHTD28 (32), to alanine, generating drICED28A.
DRONC and DCP-1 both processed drICED28A to generate a
fragment corresponding in size to the prodomain and large
subunit processed at Asp230. A slightly smaller band, probably
corresponding to the prodomain and the large subunit proc-
essed at the NH2 terminus of the large-small subunit linker,
1-Asp217 (band 2*), was also produced. However, no bands
corresponding in size to full-length drICE lacking the prodo-
main or the fully processed large subunit were observed. These
observations demonstrate that DCP-1 processes drICE in the
prodomain as well as at TETD230.
Addition of DRONC to in vitro translated drICE resulted in
production of a mature drICE large subunit lacking prodomain
sequences, but DRONC was unable to process drICE TETA230
within the prodomain (Fig. 3A). These observations suggested
that drICE cleaved by DRONC at TETD230 was autocatalyti-
cally removing its own prodomain. To test this possibility we
incubated DRONC and DCP-1 with an in vitro translated ver-
sion of drICE, drICEC211A, in which the active site cysteine was
changed to alanine. This caspase should remain inactive fol-
lowing cleavage at TETD230. As shown in Fig. 3A, DRONC
cleavage of drICEC211A resulted in the appearance of only a
single band corresponding to the prodomain and large subunit.
This observation suggests that drICE autocatalytically re-
moves its own prodomain following cleavage between the large
and small subunits. Mature drICEC211A large subunit was gen-
erated in the presence of DCP-1. This further supports the
argument that DCP-1 cleaves drICE in the prodomain as well
as at the large-small subunit boundary.
What purpose could be served by DRONC having an altered
cleavage specificity? One possibility is simply that DRONC has
unique targets other than itself, and that a different target site
preference is required for cleavage of these substrates.
DRONC’s novel cleavage site specificity, in conjunction with
the sequence of the linker between the large and small sub-
units, may also provide a mechanism for limiting DRONC’s
ability to become activated by other caspase cascades. DCP-1 or
drICE did not process DRONC to any significant extent at the
large-small subunit boundary. This is not surprising because
there are only two aspartates in the linker region between the
large and small subunits, DEYD324 and KWPD348. Based on
positional scanning synthetic combinatorial library analysis of
tetrapeptide substrates, these sequences are predicted to be
very poor substrates for all known mammalian caspases and
DCP-1 (10, 11, 45). We cannot rule out the possibility that
processing of DRONC by unknown proteases occurs at these
sites in vivo. However, because DRONC was able to process
itself in the linker region at TQTE352, but other tested caspases
were not, it seems reasonable that DRONCs altered cleavage
specificity, coupled with the lack of good target sites for other
caspases in the large-small subunit linker region, may serve at
least inpart tomakeactivationofDRONCmorestrictlyDRONC-
dependent. This may provide a mechanism for limiting cross-
talk between other caspase cascades and pathways activated
by DRONC.
Expression of an Active Site Mutant of DRONC Suppresses
FIG. 3. Processing of drICE by DRONC and DCP-1. Four 35S-labeled in vitro translated versions of drICE were generated: wild type (WT),
drICE TETA230 (D230A), in which the P1 aspartate of a caspase target site in the large-small subunit linker was altered to alanine, drICED28A
(D28A), in which the P1 aspartates of the two predicted caspase target sites in the drICE prodomain were changed to alanine, and drICEC211A
(C211A), in which the drICE active site cysteine was changed to alanine. In vitro translation products were incubated with bacterially produced
DRONC or DCP-1 as described (“Experimental Procedures”) and processed for SDS-PAGE. DRONC or DCP-1 processing of drICE resulted in the
appearance of three bands corresponding to full-length drICE without the prodomain (band 1), the prodomain and the large subunit (band 2), and
the fully processed large subunit (band 3). A fourth band (2*), observed when drICED28A was cleaved by DRONC or DCP-1, may correspond to the
prodomain and a version of the large subunit in which separation from the small subunit occurred at DRLD217 (A). Schematic showing the location
of the drICE subunits, caspase target sites and the active site pentapeptide (B).
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Cell Death in the Fly—Mutations that remove DRONC are not
available. Therefore, to examine a possible role for DRONC as
a cell death effector we generated a form of DRONC,
DRONCC318S, in which the active site cysteine was altered to
serine. Expression of similar forms of other caspases results in
a suppression of caspase activity and caspase-dependent cell
death. This may occur as a result of interaction of DRONCC318S
with the Drosophila homolog of the caspase-activating protein
Apaf-1 (30), thus preventing the Drosophila Apaf-1 from bind-
ing to wild type DRONC and promoting its activation in a
manner similar to that described for mammalian Apaf-1 and
caspase-9 (46–48). We generated transgenic Drosophila in
which DRONCC318S was expressed under the control of a pro-
moter, known as GMR, that drives transgene expression spe-
cifically in the developing fly eye (22). The eyes of these flies,
known as GMR-DRONCC318S flies (Fig. 4E), appeared similar
to those of wild type flies (Fig. 4A). To assay the ability of
DRONCC318S to block cell death, GMR-DRONCC318S flies were
crossed to flies overexpressing rpr (GMR-rpr), hid (GMR-hid),
or grim (GMR-grim) under the control of the same promoter. As
shown in Fig. 4, B-D, and previously (23–26), GMR-driven
expression of rpr, hid, or grim resulted in a small eye pheno-
type due to activation of caspase-dependent cell death. How-
ever, flies coexpressing GMR-DRONCC318S and one of the cell
death activators showed a dramatic suppression of the small
eye phenotype, indicating that cell death had been suppressed
(Fig. 4, F-H). We cannot rule out the possibility that this
suppression is a result of DRONCC318S forming nonproductive
interactions with the Drosophila Apaf-1 that block its ability to
activate other long prodomain caspases such as DCP-2/DREDD
(27). However, these possibilities notwithstanding, our results
and those of Meier et al. (28) suggest that DRONC activity is
important for bringing about rpr-, hid-, and grim-dependent
cell death.
Cell Death Induced by DRONC Expression Is Suppressed by
DIAP1, but Not by Baculovirus p35—We also generated flies
that expressed full-length wild type DRONC under GMR con-
trol. While phenotypes displayed by individuals within a line
were similar, different lines displayed eyes with various de-
grees of eye disruption, presumably owing to genomic position
effects on the expression level of the transgene (49). By manip-
ulating the number of copies of the GMR-DRONC transgene in
animals we inferred a phenotypic series in which low levels of
DRONC expression (GMR-DRONCW flies) resulted in no out-
ward phenotype (data not shown), while higher levels of ex-
pression (GMR-DRONCM flies) resulted in cell death late in
retinal development. These flies had eyes that were normal in
size and shape, but that were largely white due to a loss of
retinal pigment (Fig. 5A). Tangential sections through the eyes
of GMR-DRONCM flies showed that all retinal cells, including
photoreceptors, were missing (data not shown). Increasing
DRONC expression levels still further (GMR-DRONCS flies)
resulted in flies with small eyes (Fig. 5B), similar to those seen
in animals overexpressing rpr, hid, or grim. These observa-
tions, similar to those described by Meier et al. (28), show that
DRONC expression in the eye induces cell death in a dose-de-
pendent manner. Consistent with this interpretation, third
instar eye imaginal discs from animals expressing GMR-
DRONCS showed high levels of staining with the vital dye
acridine orange (data not shown), which is taken up and re-
tained by dying cells (50).
DIAP1, a Drosophila member of the IAP family of caspase
inhibitors, suppresses rpr-, hid-, and grim-dependent cell death
in the fly (reviewed in Ref. 21).2 We reasoned that if expression
of DRONC was activating the same pathway, then the GMR-
DRONC eye phenotype might be sensitive to the levels of
DIAP1. To test this hypothesis we decreased the amount of
DIAP1 in the eye by crossing a strong loss-of-function DIAP1
2 S. J. Yoo and C. J. Hawkins, unpublished data.
FIG. 4. DRONCC318S suppresses rpr-, hid-, and grim-dependent
cell death in the fly eye. The following genotypes are shown: wild
type (A); GMR-hid/1 (B); GMR-rpr/1 (C); GMR-grim/1 (D); GMR-
DRONCC318S/1 (E); GMR-DRONCC318S/1; GMR-hid/1 (F); GMR-
DRONCC318S/1; GMR-rpr/1 (G); GMR-DRONCC318S/1; GMR-grim/1
(H). Expression of GMR-hid, GMR-rpr, or GMR-grim resulted in a small
eye phenotype (B-D) that was suppressed by coexpression of GMR-
DRONCC318S (F-H).
FIG. 5. DRONC overexpression phenotypes in different ge-
netic backgrounds. The following genotypes are shown: GMR-
DRONCM/1 (A); GMR-DRONCS/1 (B); GMR-DRONCM/1 and th5/1
(C); GMR-DRONCS/1 and GMR-DIAP1/1 (D); GMR-DRONCS/1 and
GMR-p35 (E). Expression of intermediate levels of DRONC in the eye
(GMR-DRONCM) resulted in flies with normal sized eyes, but in which
pigment was largely absent (A). High level expression of DRONC in the
fly eye (GMR-DRONCS) resulted in flies with small eyes (B). GMR-
DRONCM flies that were heterozygous for th5, a mutation in DIAP1,
had eyes that were smaller than those of GMR-DRONCM flies (C).
Expression of GMR-DIAP1 suppressed the GMR-DRONCS small eye
phenotype (D). Expression of GMR-p35 did not significantly suppress
the GMR-DRONCS small eye phenotype (E).
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point mutant, thread 5 (th5), to GMR-DRONCM flies. th5 het-
erozygotes are phenotypically wild type. However, flies that
were heterozygous for th5, and that expressed GMR-DRONCM,
showed an enhancement of the GMR-DRONC-dependent small
eye phenotype (Fig. 5C). In contrast, small eyed GMR-DRONCS
flies that overexpressed DIAP1 because they carry a GMR-
DIAP1 transgene showed a strong suppression of the small eye
and pigment loss phenotypes (Fig. 5D). These observations,
and similar observations made by Meier et al. (28), are consist-
ent with the idea that DRONC activity is negatively regulated
by DIAP1. However, they do not exclude the possibility that
DIAP1s effects on the DRONC overexpression phenotypes are
due, at least in part, to DIAP1s ability to suppress the activity
of caspases such as drICE (33), that are activated by DRONC.
Interestingly, the DRONCS eye phenotype was not sup-
pressed by coexpression of the baculovirus caspase inhibitor
p35 (Fig. 5E) (28). This result was surprising because p35 is
generally thought of as a broad specificity caspase inhibitor
(reviewed in Ref. 51), and because expression of GMR-
DRONCC318S (Ref 28, this work) or GMR-p35 (23–26), sup-
pressed rpr-, hid-, and grim-dependent cell death in the fly
eye.
To characterize DRONCs interactions with caspase inhibi-
tors further, in isolation from other Drosophila cell death reg-
ulators, we made use of a yeast caspase activity reporter sys-
tem in which caspase activity is monitored as a function of cell
survival. In this system, high level expression of active
caspases kills yeast, and this death is suppressed by coexpres-
sion of proteins that inhibit caspase activity (39, 52). Yeast
were transformed with a galactose-inducible expression vector
(carrying the GAL1 promoter) that was either an empty vector,
or that contained wild type DCP-1, wild type DRONC, or the
FIG. 6. Interaction of DRONC with
Drosophila cell death regulators in
Saccharomyces cerevisiae. GAL1-
driven expression of DCP-1 (DCP1) or
DRONC (DRONC) killed yeast. GAL1-
driven expression of an empty vector (vec-
tor) or DRONCC318S (C318S) had no effect
on yeast cell growth (A). GAL1-driven ex-
pression of DRONC resulted in yeast cell
death that was suppressed by ADH1-
driven expression of DIAP1 but not
DIAP2 or p35 (B). Yeast expressing a
Myc-tagged fragment of human PARP
(Myc-PARP337) or baculovirus p35 (p35)
carried either an empty GAL1 expression
plasmid (vector) or one containing
DRONC or DCP-1. Extracts were made
from these cells following induction of the
GAL1 promoter and processed for SDS-
PAGE and Western blotting. Western
blots were probed with antibodies against
the Myc epitope (top panel) or p35 (bottom
panel) (C). CUP1-driven expression of
DIAP1 in the presence of 100 mM copper
blocked DRONC-dependent yeast cell
death. GAL1-driven expression of HID or
GRIM, but not RPR, blocked the survival
of these cells (D).
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catalytically inactive DRONCC318S. Transformants were spot-
ted as a series of 5-fold serial dilutions onto glucose plates to
indicate the number of cells, and onto galactose plates to induce
expression of the caspase. As shown in Fig. 6A, cells expressing
the empty vector grew well on glucose or galactose-containing
media. However, cells expressing GAL1-DCP-1 or GAL1-DRONC
failed to grow on galactose-containing media. Importantly, cells
expressing GAL1-DRONCC318S grew on galactose as well as
cells expressing the empty vector. Thus, DRONC expression
kills yeast and this killing requires caspase activity.
To determine if DRONC activity could be inhibited by known
or suspected caspase inhibitors we carried out experiments in
which GAL1-DRONC expression was induced in cells carrying
a second vector in which expression was driven by the consti-
tutive ADH1 promoter. This vector was either empty, or carried
the coding region for DIAP1, a second cell death inhibiting
Drosophila IAP, DIAP2 (reviewed in Ref. 21), or baculovirus
p35. As shown in Fig. 6B, expression of ADH-DIAP1 blocked
DRONC-dependent cell death, but expression of ADH-DIAP2
or ADH-p35 did not. DIAP2 interacts with RPR, HID, and
GRIM (53, 54), and blocks rpr-, hid-, and grim-dependent cell
death (24, 54–56). However, interactions between DIAP2 and
lepidopteran or Drosophila caspases have not been observed
(57).3 DIAP2 may suppress death by interacting with uniden-
tified caspases; alternatively DIAP2 may function primarily to
inhibit the activity of caspase-activating proteins such as RPR,
HID, and GRIM. Inhibition of caspase activity by p35 is asso-
ciated with p35 cleavage, resulting in the formation of a stable
p35-caspase complex (58, 59). Because of DRONC’s unique
cleavage specificity we asked if DRONC was in fact able to
cleave p35. Yeast were transformed with an ADH1 expression
plasmid carrying the coding region for a Myc- tagged fragment
of a common caspase substrate, poly(ADP-ribosyl)transferase
(PARP) (reviewed in Ref. 60), or baculovirus p35. These yeast
also carried GAL1 vectors that were either empty, or that
contained DRONC or DCP-1. Extracts were made from yeast
grown under GAL1 inducing conditions and these were proc-
essed for SDS-PAGE and Western blotting using anti-Myc or
p35 antibodies. As shown in Fig. 6C, only the full-length sub-
strate band was seen in yeast expressing Myc-PARP or p35 in
isolation or in combination with DRONC. In contrast, yeast
expressing Myc-PARP or p35 in combination with DCP-1
showed immunoreactive bands of sizes expected following
caspase cleavage. These results and those of Meier et al. (28)
further support the idea that DRONC has a unique cleavage
specificity, and strongly suggest that DRONC-dependent cell
killing is not inhibited by p35 because DRONC does not recog-
nize and/or cleave the caspase target site in p35.
We found that bacterially produced DIAP1 did not inhibit the
activity of fully processed (prodomainless) DRONC in vitro
(data not shown). This stands in contrast to our observation
that DIAP1 inhibited DRONC-dependent yeast cell death.
These two sets of observations are not necessarily incompati-
ble. The DRONC prodomain has been shown to bind to DIAP1
(28). Also the small eye phenotypes associated with overexpres-
sion of full-length DRONC (Ref. 28 and this work), but not
versions of DRONC lacking the prodomain (28), are sensitive to
the levels of DIAP1. These observations suggest that effective
DIAP1 inhibition of DRONC activity requires the DRONC
prodomain (28). DIAP1 may, for example, block a step of
DRONC processing, and thus DRONC activation. Alterna-
tively, DIAP1 may block the activity of partially processed,
prodomain containing, versions of DRONC. Other observations
pointing toward an important role for the prodomain in some
DIAP1-caspase interactions comes from the finding that drICE
lacking its prodomain was also not inhibited by DIAP1 (39),
while versions containing the prodomain were (33). We were
unable to generate an active version of DRONC containing its
prodomain (DRONCpD4A), and have thus been unable to di-
rectly test the hypothesis that DIAP1 inhibits DRONC activa-
tion or activity. Nonetheless, the observations that DIAP1
physically interacts with the DRONC prodomain, that DRONC-
dependent death is sensitive to the levels of DIAP1 in flies and
in yeast, and that there is a good correlation between IAP-de-
pendent inhibition of caspase-dependent phenotypes in yeast
and caspase activity in vitro (33, 39), argue that this is likely to
be the case.
HID and GRIM Suppress DIAP1s Ability to Inhibit DRONC-
dependent Yeast Cell Death—Genetic and biochemical evidence
suggests that one mechanism by which RPR, HID, and GRIM
promote apoptosis is by blocking DIAP1s ability to inhibit
caspase activation or activity, thereby promoting caspase-de-
pendent cell death (33, 34, 57). To determine if DRONCs activ-
ity could be regulated in a similar manner we tested whether
RPR, HID, or GRIM could interfere with DIAP1-dependent
inhibition of DRONC-dependent yeast cell death. We generated
yeast in which DRONC was expressed under GAL1 control and
DIAP1 was expressed under the control of the copper-inducible
CUP1 promoter. We then introduced into these yeast a third
GAL1 vector that was either empty or that expressed RPR,
HID, or GRIM. As shown in Fig. 6D, cells expressing GAL1-
DRONC and empty vectors died when plated on medium con-
taining galactose and 100 mM copper, but cells expressing
GAL1-DRONC and CUP1-DIAP1 survived. Coexpression of
GAL1-RPR had no effect on the survival of yeast expressing
GAL1-DRONC and CUP1-DIAP1. However, coexpression of
GAL1-HID or GAL1-GRIM completely blocked the survival of
these cells (Fig. 6D). RPR, HID, or GRIM expression in isola-
tion has little or no effect on yeast cell growth (33). Thus, while
these experiments do not exclude the possibility that HID and
GRIM might alter DRONC activity directly, they are consistent
with other observations arguing that these proteins mediate
their effects on caspase activity, and thus presumably caspase-
dependent yeast cell killing, by virtue of their interactions with
DIAP1 (33, 34).
We cannot formally exclude the possibility that DRONC
normally functions to regulate cellular processes other than
cell death since mutants that eliminate DRONC are not avail-
able. However, the observations by ourselves and others (28)
demonstrating that dominant negative forms of DRONC block
rpr-, hid-, and grim-dependent cell death, that DRONC kills,
and that DRONC interacts with drICE, DIAP1, HID, and
GRIM, all support the idea that DRONC plays an important
role in promoting apoptotic cell death. However, DRONC ac-
tivity is not inhibited by p35, which is a potent inhibitor of rpr-,
hid-, and grim-dependent cell death in the fly. Interestingly, an
analogous p35-insensitive, IAP-sensitive, cell death-activating
cleavage event has also been described in lepidopteran cells.
Baculovirus infection of lepidopteran cells elicits a cell death
response that is associated with cleavage and activation of the
lepidopteran caspase Sf caspase-1 (61–63). This cleavage is
blocked by viral IAPs, but not by p35. Instead, p35-dependent
death suppression in this system is associated with inhibition
of active Sf caspase-1 (62, 63). Sf caspase-1 cleavage is probably
mediated by p35-insensitive proteases and not by oligomeriza-
tion followed by autocatalysis (63). This is because the Sf
caspase-1 prodomain is short and lacks death effector domain
or caspase recruitment domain sequences that might mediate
the oligomerization required for this mode of activation (64).
DRONC-dependent killing of mammalian cells was blocked by3 C. J. Hawkins and S. J. Yoo, unpublished observations.
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p35 (18). However, based on our observation that DRONC
cleaves the executioner caspase drICE at the same site as the
more typical caspase DCP-1, as well as the above noted find-
ings in lepidopteran cells, it seems likely that p35 blocked
DRONC-dependent killing of mammalian cells by inhibiting
the activity of caspases activated by DRONC. Further indirect
evidence supporting a possible role for a caspase such as
DRONC in apoptosis initiation, that is p35-insensitive and has
a novel cleavage specificity, comes from the observation that
cleavage of DCP-2/DREDD, which occurs following overexpres-
sion of RPR, HID, or GRIM, is p35-insensitive (17). Finally, it
is worth noting that the caspase DECAY lacks aspartate resi-
dues in the region predicted to span the large-small subunit
boundary (Fig. 1) (19). This indicates that processing of this
caspase, if it occurs, must happen at other residues.
Models for how DRONC might function as a death activator
must explain how DRONC-dependent death can be sensitive to
p35, while DRONC itself is p35-insensitive. In considering
DRONC-dependent cell death it is important to recognize that
the cell death seen when DRONC is expressed in the eye under
the control of the GMR promoter may be the result of unphysi-
ologically high levels of DRONC activity, which lead to cleav-
age of inappropriate substrates and cell death. This DRONC-
dependent death would be expected to be sensitive to the levels
of DIAP1 because DIAP1 inhibits DRONC activity, but insen-
sitive to p35 because DRONC does not interact with p35 (see
Figs. 5 and 6). drICE is p35-inhibitable and DRONC processes
drICE between the large and small subunits, presumably acti-
vating it. However, DRONC does not process the drICE prodo-
main. Versions of drICE that contain prodomain sequences are
inhibited by DIAP1 (33), but drICE lacking its prodomain is
DIAP1-insensitive (39). Thus, the normal levels of DIAP1 pres-
ent in the eye may act as a buffer to limit the activity of drICE
that has been processed by DRONC alone. This would also
contribute to making the DRONC overexpression phenotype
p35-insensitive. In this and as discussed below we refer specif-
ically to drICE as a target of DRONC and as a likely execu-
tioner caspase based on the observations presented here and
elsewhere (15, 28, 30, 32). However, other executioner caspases
may be important and behave similarly.
There are several ways in which DRONC could play an
important role in initiating p35-sensitive cell death. One pos-
sibility is simply that the levels of DRONC activity required to
activate p35-inhibitable executioner caspases are low enough
that DRONC activation in isolation does not induce apoptosis.
A second possibility is that upstream death signals lead to
activation of DRONC as well as other caspases with more
traditional cleavage specificities. In this model DRONC and the
other initiator caspases both cleave and activate executioner
caspases such as drICE. If any of these caspases process drICE
in the prodomain (as DCP-1 does (Fig. 3A)) this would promote
the formation of a DIAP1-insensitive form of drICE, thereby
presumably amplifying drICE activity. In this scenario, as
above, it is proposed that the levels of DRONC activity are low
compared with those present during DRONC overexpression.
Therefore p35 should be able to block cell death since p35 is
able to inhibit drICE-activating caspases with traditional
caspase cleavage sites, as well as drICE itself. Finally, up-
stream death signals leading to activation of DRONC may
result in the inhibition of caspase inhibitors such as DIAP1 as
a consequence of its interacting with molecules such as RPR,
HID, or GRIM (33). In this model, DRONC activation of exe-
cutioner caspases such as drICE, coupled with a decrease in
DIAP1 function, would lead to increased activation of drICE,
which is p35 inhibitable. As above, this model assumes that the
levels of DRONC activity induced by upstream cell death sig-
nals are not sufficient to promote significant cell death in
isolation. Clearly these models are not mutually exclusive. An
important test of each of these models will be to determine if
DRONC activation occurs following rpr, hid, or grim overex-
pression, even if cell death is blocked by coexpression of p35.
Several caspases, including Drosophila DRONC and C. el-
egans CSP-1 and CSP-2, have divergent active site pentapep-
tide sequences. We showed that one of these, DRONC, has a
novel cleavage site specificity, cleaving COOH-terminal to glu-
tamate as well as aspartate residues. Our observations with
DRONC are important because they suggest that some caspase-
dependent processes have remained unseen using caspase in-
hibitors such as p35. It will be interesting to see if cell deaths,
or steps in cell death signaling that have been thought to be
caspase-independent, and thus not amenable to caspase-based
therapeutics, are in some cases regulated by caspases with
nontraditional cleavage specificities.
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